DavidMichaelNeskeyMDMSCR, FACS

Head & Neck Oncologic Surgery, Head & Neck Plastic Surgery

Director Head and Neck Translational Research Program Sarah Cannon Research Institute Trident Health HCA Healthcare

Overview of Dr. Neskey

I received my medical degree from Albany Medical College with a distinction in research in 2006 followed by a residency in Otolaryngology Head and Neck Surgery at the University of Miami. I then completed a fellowship in head and neck surgical oncology at MD Anderson Cancer Center in Houston. This training experience was comprised of two years dedicated to translational science research followed by a year committed to head and neck surgical oncology. I was on faculty at the Medical University of South Carolina in the Department of Otolaryngology–Head and Neck Surgery until 2021. I currently serve as the Director of Head and Neck Translational Research at Sarah Cannon Research Institute.

My clinical focus is on the care of patients with benign and malignant neoplasias of the head and neck including oral cavity, oropharyngeal, laryngeal lesions, and skullbase, advanced melanoma and nonmelanoma skin cancers, and lesions of the salivary glands, thyroid and parathyroids. His specific interests are squamous cell carcinoma of the oral cavity and oropharynx along with advanced skin cancer and skull base tumors.

4. I have published over 50 peer reviewed articles and book chapters focused on the
molecular pathways and genomic alterations associated with head and neck squamous cell carcinoma. In addition, I have been the principal investigator for several ongoing trials, including a Phase II investigator-initiated trial of nivolumab as a presurgical treatment for patients with oral cavity cancer. I have been continuously funded through the NIH/NIDCR since 2016. I am board certified by the American Board of Otolaryngology and am a member of the American Head and Neck Society, American Academy of Clinical Research, and a Fellow of the American College of Surgeons.

I am currently seeing patients at the Head and Neck Specialists clinic at Trident Medical Center

Office
9228 Medical Plaza Dr
Charleston, SC 29406
Book by Phone+1(803) 941-5381

Fax+1 843-764-4512

Education & Training

University of Texas Health Science Center at HoustonFellowship, Otolaryngology - Head and Neck Surgery, 2011 - 2014
University of Miami/Jackson Health SystemResidency, Otolaryngology - Head and Neck Surgery, 2006 - 2011
Albany Medical CollegeClass of 2006
Colby CollegeB.A., Biology, 1995 - 1999

Certifications & Licensure

SC State Medical License 2014 - 2025
GA State Medical License 2022 - 2023
TX State Medical License 2013 - 2015
American Board of Otolaryngology - Head and Neck Surgery Otolaryngology

Awards, Honors, & Recognition

Best Basic Science Poster 8th International Conference on Head & Neck Cancer, 2012
Resident Research Award 2009-2010
Distinction in Research 2005-2006
Fellow (FAAO-HNS) American Academy of Otolaryngology - Head and Neck Surgery
Join now to see all

Clinical Trials

Trial of Nivolumab as a Novel Neoadjuvant Pre-Surgical Therapy for Locally Advanced Oral Cavity Cancer Start of enrollment: 2017 May 30
Completed
Phase 2
Memory Phenotype and PD-1 Inhibition Response in Oral Cancer Start of enrollment: 2019 Feb 08
Terminated

Publications & Presentations

PubMed

405 citations
Integrative Genomic Characterization of Oral Squamous Cell Carcinoma Identifies Frequent Somatic Drivers
Curtis R. Pickering, Jiexin Zhang, Suk Young Yoo, Linnea Bengtsson, Shhyam Moorthy
Cancer Discovery. 2013-07-01
22 citations
Response and recurrence correlates in individuals treated with neoadjuvant anti-PD-1 therapy for resectable oral cavity squamous cell carcinoma
Sixue Liu, Hannah M. Knochelmann, Shirley H. Lomeli, Aayoung Hong, Mary S. Richardson
Cell Reports. Medicine. 2021-10-19
37 citations
Neoadjuvant presurgical PD-1 inhibition in oral cavity squamous cell carcinoma
Hannah M. Knochelmann, Joshua D. Horton, Sixue Liu, Kent Armeson, John M. Kaczmar
Cell Reports. Medicine. 2021-10-19

Journal Articles

Evaluating Adjuvant Therapy with Chemoradiation vs Radiation Alone for Patients with HPV-Negative N2a Head and Neck Cancer
David M Neskey, Patrik Pipkorn, Joseph Zenga, Evan M Graboyes, JAMA Otolaryngology–Head & Neck Surgery
Association of Treatment Delays with Survival for Patients with Head and Neck Cancer
Brian Nussenbaum, David M Neskey, Evan M Graboyes, Shaun Nguyen, Graham W Warren, JAMA
Prognostic Factors Associated Decreased Survival in Acinic Cell Carcinoma
Neskey DM, Klein JD, Hicks S, Garden AS, Bell D, El-Naggar AK, Kies MS, Weber RS, Kupferman ME, JAMA Otolaryngol Head Neck Surg, 9/26/2013
Chk1/2 inhibition overcomes the cisplatin resistance of head and neck cancer cells secondary to the loss of functional p53
Gadhikar MA, Sciuto MR, Ortega Alves MV, Pickering CR, Osman AA, Neskey DM, Zhao M, Fitzgerald AL, Myers JN, Frederick MJ, Mol Cancer Ther. Mol Cancer Ther, 9/1/2013
Elevated level of serum growth differentiation factor 15 is associated with oral leukoplakia and oral squamous cell carcinoma
Yang CZ, Ma J, Luo QQ, Neskey DM, Zhu DW, Liu Y, Myers JN, Zhang CP, Zhang ZY, Zhong LP, J Oral Pathol Med, 5/26/2013
Integrated genomic characterization of oral cavity squamous cell carcinoma identifies frequent genomic drivers
Pickering CR, Zhang J Suk, Yoo SY, Neskey DM, Xie TX, El-Naggar AK, Weinstein JN, Wang J, Gibbs RA, Wheeler DA, Myers JN, Frederick MJ, Cancer Discovery, 4/25/2013
Induction chemotherapy decreases the rate of distant metastasis in patients with head and neck squamous cell carcinoma but does not improve survival or locoregional co...
Ma J, Liu Y, Huang XL, Zhang ZY, Myers JN, Neskey DM, Zhong LP, Oral Oncol, 7/14/2012
Nasal, septal, and turbinate anatomy and embryology
Neskey DM, Eloy JA, Casiano RR, Otolaryngology Clinics of North America, 1/1/2009
HMGA2 expression in uterine leiomyomata and myometrium: quantitative analysis and tissue culture studies
Gross KL, Neskey DM, Manchanda N, Weremowicz S, Kleinman MS, Nowak RA, Ligon AH, Rogalla P, Drechsler K, Bullerdiek J, Morton CC, Genes, Chromosomes, & Cancer, 9/1/2003
Fusion transcripts involving HMGA2 are not a common molecular mechanism on uterine leiomyomata with rearrangements in 12q15
Quade BJ, Weremowicz S, Neskey DM, Vanni R, Ladd C, Dal Cin P, Morton CC, Cancer Research, 3/1/2003
Intravenous leiomyomatosis is characterized by a der(14)t(12;14)(q15;q24)
Dal Cin P, Quade BJ, Neskey DM, Kleinman MS, Weremowicz S, Morton CC, Genes, Chromosomes, & Cancer, 2/1/2003
Intravenous Leiomyomatosis: molecular and cytogenetic analysis of a case
Quade BJ, Dal Cin P, Neskey DM, Weremowicz S, Morton CC, Modern Pathology, 3/1/2002
Chromosomal Translocation t(8;12) Induces Aberrant HMGIC Expression in Aggressive Angiomyxomas of the Vulva
Nucci MR, Weremocicz S, Neskey DM, Sornberger K, Tallini G, Morton CC, Quade BJ, Genes, Chromosomes, and Cancer, 10/1/2001
Join now to see all

Books/Book Chapters

Plastic reconstructive and aesthetic surgery.
Chapter: Head and Neck Malignancy.
Neskey DM and Weed DWorld Scientific Publishing Ltd., Hackensack, NJ2011

Abstracts/Posters

Surgical Salvage for Recurrent Oral Cavity Squamous Cell Carcinoma.
Neskey DM, Boerner RM, Ward AW, Roberts DB, Kuoni SM, Stoneking JN, Tyler MA, Alukual P, Hutcheson KA, Weber RS, Sturgis EM, Myers JN, Zafereo ME, 5th World Congress - IFNOS and AHNS, New York, NY, 7/26/2014
Prognostic Factors Associated Decreased Survival in Acinic Cell Carcinoma.
Neskey DM, Klein JD, Garden AS, Bell D, El-Naggar AK, Kies MS, Weber RS, Kupferman ME, American Head and Neck Society, Orlando, FL, 4/10/2013
MK-1775, A selective Wee1 kinase Inhibitor, Overcomes Cisplatin Resistance Associated with High Risk TP53 Mutations in Squamous Cell Carcinoma of the Head and Neck.
Osman AA, Monroe M, Alves Ortega M, Neskey DM, Patel AA, Chuang HC, Mason L, Meyn RE Byers L, Katsonis P, Lichtarge O, Myers JN, American Academy of Cancer Research, Washington, DC, 4/6/2013
Reactive Oxygen Species and p21Waf1/Cip1 are Essential for Radiation-Induced Accelerated Senescence of Head and Neck Cancer Cells.
Fitzgerald AL, Osman AA, Neskey DM, Patel A, Skinner H, McDonnell T, Myers JN, American Association for Cancer Research, Washington, DC, 4/6/2013
TP53 mutational status stratified by Evolutionary Gradient and Structure Model is a predictive biomarker of platinum based chemotherapy resistance in head and neck squ...
Fitzgerald AL, Osman AA, Neskey DM, Patel A, Skinner H, McDonnell T, Myers JN, 8th International Conference on Head & Neck Cancer, Toronto, Canada, 7/23/2012
TP53 Mutational Status Stratified by Evolutionary Gradient and Structure Model is a Prognostic Biomarker of Overall Survival in Head and Neck Squamous Cell Carcinoma.
Neskey, DM, Osman, AO, Myers, JN, 8th International Conference on Head & Neck Cancer, Toronto, Canada, 7/21/2012
Genomic analysis of oral cavity squamous cell carcinoma identifies frequent chromosomal abnormalities and an association between loss of chromosome 8p and increased ex...
Cortez, E, Frederick, MJ, Neskey, DM, Zhang, J, Wang, J, Myers, JN, Pickering, C, 8th International Conference on Head & Neck Cancer, Toronto, Canada, 7/21/2012
Functional Outcomes after Paraganglioma Resections are Independent of Tumor Site.
Neskey, DM, Modh, R, Goldin, G, Hatoum, G, Sargi, Z, American Academy of Otolaryngology and Head and Neck Surgery, Oral Presentation for Head and Neck Scientific Program, San Diego, CA, 10/6/2009
CD44, CD29, and CD 133 as potential markers for Cancer Stem Cells in Head and Neck Squamous Cell Carcinoma.
Perez, A, Neskey, DM, Pereira L, Goodwin WJ, Slingerland, J, Franzmann, E, American Association of Cancer Research Conference, Denver, CO, 4/18/2009
High-resolution computed tomography analysis of the frontal sinus ostium.
Neskey, DM, Eloy, JA, Vivero, R, Casiano, RR, Ruiz, JW, American Rhinologic Society Conference, Chicago, IL, 9/20/2008
The Matrix-Derived Endogenous Inhibitors of Angiogenesis, Endostatin and Anastellin, Affect Distinct Map Kinase Signaling Pathways.
Neskey DM, Ambesi A, McKeown-Longo, P, American Association of Cancer Research Conference, Anaheim, CA, 4/16/2005
Understanding the Molecular Mechanism of Dysregulated HMGA2 Expression in Uterine Leiomyomata with 12q15 Rearrangements.
Neskey DM, Dal Cin P, Weremowicz S, Quade BJ, Morton CC, American Society of Human Genetics Conference, Concurrent Slide Session 43: Cytogenetics / Cancer Cytogenetics, Baltimore, MD, 10/15/2002
Polyomavirus Large T Antigen / MMTV Transgenic Mice as a Model of Uterine Leiomyomata.
Neskey DM, Ligon, AH, Quade, BJ, Morton, CC, American Society of Human Genetics Conference, San Diego, CA, 10/12/2001
Mullerian Adenocarcinoma Is Not Characterized By Marked Chromosomal or Genomic Instability.
Quade BJ, Neskey DM, Nucci MR, Dal Cin P, Wang T-Y, Proceedings of the 90th annual meeting of the United-States - Canadian Academy of Pathology, Modern Pathology, Atlanta, GA, 3/1/2001
Intravenous Leiomyomatosis: Is There A Genetic Link With Uterine Leiomyomata?
Dal Cin P, Neskey DM, Weremocicz S, Morton CC, Quade BJ, Proceedings of the 90th annual meeting of the United-States - Canadian Academy of Pathology, Modern Pathology, Atlanta, GA, 3/1/2001
Join now to see all

Authored Content

Evaluating Adjuvant Therapy with Chemoradiation vs Radiation Alone for Patients with HPV-Negative N2a Head and Neck CancerAugust 2020

Press Mentions

Jessica Thaxton, PhD with MUSC’s Hollings Cancer Center Secures $3.4m to Look at Immunotherapy and Cell StressJuly 25th, 2020
New Associate Directors at Hollings Cancer Center to Advance Cancer ImmunologyApril 25th, 2020
Studies Show How to Boost Immunotherapy Effectiveness for Patients with Oral-Cavity Squamous Cell CarcinomaNovember 5th, 2021

Grant Support

Defining the role of CD26 in checkpoint blockaded induced tumor immunityNational Institute of Dental and Craniofacial Research2020–2022
Paul Calebresi Clinical and Translational Oncology Training ProgramNational Cancer Institute2020–2021
The tumor suppressor capability of p53 is dependent on Non-muscle Myosin IIA function in Head and Neck Cancer.NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH2016–2019
Paul Calebresi Clinical and Translational Oncology Training ProgramNational Cancer Institute2014–2016